Document Detail

Role of biomarkers in chemotherapy-induced cardiotoxicity.
MedLine Citation:
PMID:  20728699     Owner:  NLM     Status:  MEDLINE    
Chemotherapy-induced cardiotoxicity remains an unresolved problem strongly impacting the quality of life and the overall survival of cancer patients. The main strategy for minimizing cardiotoxicity is early detection of high-risk patients and prompt prophylactic treatment. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategies. Measurement of cardiospecific biomarkers can be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. In particular, the role of troponin in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing cardiac dysfunction and cardiac events is clearly emerging as a new effective approach. Therefore, we propose troponin as a criterion standard marker for the assessment of cardiac risk of both old and new antineoplastic treatments, and its evaluation should be included among the criteria utilized to define cardiotoxicity.
Daniela Cardinale; Maria Teresa Sandri
Related Documents :
7994859 - Survival and predictors of survival in patients with congestive heart failure due to ch...
2046709 - Predictors of event-free survival after balloon aortic valvuloplasty.
9680019 - Prehospital pulseless, unconscious penetrating trauma victims: field assessments associ...
320159 - Probability of survival in hypertensive and nonhypertensive patients on maintenance hem...
15754279 - Dialyzer membrane permeability and survival in hemodialysis patients.
11975839 - Cardiac amyloidosis: a case report and therapeutic implications.
12496859 - Maximum androgen-blockade with medical or surgical castration in advanced prostate canc...
18084249 - The prognostic value of histological grading of posterior fossa ependymomas in children...
20425409 - Prognostic factors in low-grade non-hodgkin lymphomas.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  53     ISSN:  1873-1740     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-09-27     Revised Date:  2013-05-02    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  121-9     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Biological Markers / blood
Early Diagnosis
Heart Diseases / blood,  chemically induced,  diagnosis*,  prevention & control
Natriuretic Peptides / blood
Neoplasms / drug therapy*
Predictive Value of Tests
Risk Assessment
Troponin / blood*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Biological Markers; 0/Natriuretic Peptides; 0/Troponin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
Next Document:  Management of trastuzumab-related cardiac dysfunction.